Busque Philippe 4

What Happened
Philippe Busque, Senior VP, Global Sales and Services at Cytek Biosciences (CTKB), had multiple RSU awards convert to common stock on May 18, 2026. A total of 10,464 shares were acquired upon conversion/vesting (1,024 + 1,473 + 2,416 + 5,551). To satisfy withholding tax obligations, 2,685 of those shares were surrendered to the issuer (disposed) at $3.55 per share, for reported value of $9,532. The filing was submitted on May 20, 2026.

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (timely filing).
• Shares acquired (conversion/vesting of RSUs): 10,464 shares.
• Shares surrendered for tax withholding: 2,685 shares at $3.55/share = $9,532.
• Footnotes: F1–F6 indicate these were Restricted Stock Units (RSUs), each converting to one share; the withheld shares were surrendered to the issuer to satisfy tax withholding; multiple RSU awards have staggered 4‑year vesting schedules as detailed in the filing.
• Shares owned after the transaction: not stated in the Form 4 filing.

Context
This was not an open-market sale or purchase — it reflects the routine conversion/vesting of RSUs and a cashless-style withholding of shares to cover taxes. For retail investors, such tax-withholding disposals are common and typically do not signal a deliberate sale of shares for investment reasons. The entries labeled as derivative conversions with $0.00 reflect the RSU-to-share conversion rather than a paid option exercise.